News Alnylam a ‘premier league’ addition to UK biotech UK base will be operational HQ, Switzerland to be official head office
Views & Analysis Coming of age: Alnylam and the RNAi revolution Alynylam has a crucial two years ahead of it, but it and RNAi could be about to come of age.
News Alnylam gears up for first RNAi therapeutic filing in 2017 US biotech Alnylam says it could file its first product in 2017, a rare disease drug using what has long promised to be a revolutionary approach, RNA interference.
News Bayer hits "turning point" in recovery plan, says CEO Bayer's pharma unit has reached a "turning point" in its growth trajectory as sales of new medicines rose 6.4% in Q3, says CEO Bill Anderson.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
